Welcome to our dedicated page for Camp4 Therapeutics news (Ticker: CAMP), a resource for investors and traders seeking the latest updates and insights on Camp4 Therapeutics stock.
CAMP4 Therapeutics Corporation reports developments as a clinical-stage biopharmaceutical company developing regulatory RNA-targeting therapeutics designed to upregulate gene expression and restore healthy protein levels in genetic diseases. Company updates center on its RAP Platform, regRNA mapping, antisense oligonucleotide candidates and CMP-002 for SYNGAP1-related disorder, along with regulatory submissions, orphan-drug designation and natural-history research collaborations.
Recurring news also includes financial results, research and development spending, financing activity, business-development agreements such as the GSK collaboration, board and governance changes, inducement equity grants under Nasdaq rules and investor conference participation.
CalAmp (CAMP) reported first-quarter results for fiscal year 2021, revealing consolidated revenue of $80.2 million, a 10% decline year-over-year, primarily driven by reduced Telematics Systems revenue due to COVID-19. Software & Subscription Services revenue rose 10% to $28.0 million, comprising 35% of total revenue. A net loss of $14.4 million, or $0.42 per share, was recorded, alongside a non-GAAP net income of $0.6 million.
The company announced strategic shifts, including exiting the automotive financing sector to improve gross margins.
CalAmp (Nasdaq: CAMP) has announced the release date for its fiscal 2021 first quarter results, scheduled for June 25, 2020, after market close. The company will hold a conference call at 4:30 p.m. Eastern on the same day to discuss these financial results. Investors can access the call via webcast on the Investor Relations page of CalAmp's website or by dialing in using the provided conference ID. CalAmp is known for its technology solutions in mobile IoT deployments, with over 20 million installed products globally.
CalAmp (Nasdaq: CAMP) appointed Nathan Lowstuter as the new Senior Vice President of Global Supply Chain and Operations. With over 20 years of experience in supply chain management and operations, Lowstuter will enhance CalAmp's efficiency and product delivery. His previous role at Proterra Inc. involved developing supply chain strategies that supported significant business growth. Lowstuter holds an MBA from the University of Southern California and is a certified Six Sigma Black Belt. This appointment aims to streamline operations as CalAmp scales its global presence.